Want to invest in a fast-paced medical device Start Up?
Our investor support network
The Nebu~Flow® technology is a new generation of nebulisers that enables inhalation delivery of a wider range of formulations than possible with current nebuliser technologies, transforming respiratory drug delivery. In particular, our platform enables inhalation delivery of biologics, the next generation of inhaled drugs.
Nebu-Flow® has secured more than £3m of funding including awards, grants and £1.75m equity investment from Foresight Williams Technology, Science Creates Venture, Ascension and SIS Venture.
We are currently looking to raise our next investment round, so please get in touch if you would like to join our journey and help more than 500m people to breathe easier.
Respiratory disorders are the leading cause of death and disability in the world.
One of the main users of nebulisers are 300m people suffering from Chronic Obstructive pulmonary disorders (COPD). COPD is the 3rd leading cause of death globally and number of incidents are increasing as people are living longer along with the environmental factors such as higher air pollution and global warming.
Our products will be launched in the £0.8bn nebuliser device market (8% CAGR) as a stand-alone device and in the £35bn respiratory drug market (6% CAGR) as drug-device combination product.
doses of drugs are being nebulised each minute!
Nebu~Flow® has received a number of awards
Our journey has been supported by a number of awards, recognising our scientific and commercial achievements.
Would you like to learn more about Nebu~Flow®?
